How does Cosentyx (secukinumab) affect the body’s response to inactive (killed) vaccines?
Cosentyx is an immune-targeted biologic that blocks interleukin-17A (IL‑17A). Because IL‑17A plays a role in immune signaling and host defense, Cosentyx can reduce how strongly the body responds to vaccines. In practice, this is why guidance often emphasizes completing age-appropriate vaccinations before starting treatment when possible.
For inactive vaccines specifically (vaccines that do not contain live organisms), the key point is that they are generally considered safe to give to people taking immunomodulating therapies, but the immune response (antibody levels and/or protection) may be lower than in people not taking the drug. This does not mean inactive vaccines stop working; it means the degree of protection may be reduced.
Are inactive vaccines safe to receive while on Cosentyx?
Inactive vaccines (including many flu shots and other non-live vaccines) are typically considered safe because they do not contain live pathogens. The more important concern is immunogenicity—whether the immune system mounted a strong enough response for lasting protection while on IL‑17A blockade.
What vaccines are most affected, and what should patients do about timing?
People on Cosentyx are generally advised to:
- Review and update routine vaccinations before starting therapy when feasible.
- If a vaccine is needed after starting Cosentyx, discuss timing with the prescribing clinician, since the medication’s ongoing effect on immune signaling may influence the strength of the response.
This timing advice matters most for vaccines where stronger antibody responses are important for protection, such as seasonal influenza and certain adult vaccines (based on age, risk factors, and local recommendations).
Can Cosentyx interfere with booster shots or re-vaccination?
Boosters rely on the ability to generate (or re-generate) antibody responses. Because Cosentyx may blunt vaccine-induced immune responses, some clinicians may consider whether a booster is still worthwhile and whether immune response levels might be lower than expected. The right plan depends on the specific vaccine and the patient’s risk.
What about live vaccines—are they treated differently?
Inactive vaccines are the focus of your question, but it’s important clinically that live vaccines are usually handled more cautiously with immunomodulators. The difference is that live vaccines contain replicating organisms, which poses a different risk profile than non-live (inactive) vaccines.
If you tell me which inactive vaccine you mean (for example, flu shot, pneumococcal, hepatitis, shingles “shot” vs live zoster, COVID-19 formulation), I can narrow the answer to the most relevant timing and expectations for Cosentyx.
Sources